Cargando…

Activity of opioid ligands in cells expressing cloned mu opioid receptors

BACKGROUND: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharagozlou, Parham, Demirci, Hasan, David Clark, J, Lameh, Jelveh
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140036/
https://www.ncbi.nlm.nih.gov/pubmed/12513698
http://dx.doi.org/10.1186/1471-2210-3-1
_version_ 1782120593530814464
author Gharagozlou, Parham
Demirci, Hasan
David Clark, J
Lameh, Jelveh
author_facet Gharagozlou, Parham
Demirci, Hasan
David Clark, J
Lameh, Jelveh
author_sort Gharagozlou, Parham
collection PubMed
description BACKGROUND: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand β-endorphin and the common mu agonist, morphine. RESULTS: Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = β-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine ≥ xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> β-endorphin. CONCLUSION: These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.
format Text
id pubmed-140036
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1400362003-01-20 Activity of opioid ligands in cells expressing cloned mu opioid receptors Gharagozlou, Parham Demirci, Hasan David Clark, J Lameh, Jelveh BMC Pharmacol Research Article BACKGROUND: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand β-endorphin and the common mu agonist, morphine. RESULTS: Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = β-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine ≥ xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> β-endorphin. CONCLUSION: These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors. BioMed Central 2003-01-04 /pmc/articles/PMC140036/ /pubmed/12513698 http://dx.doi.org/10.1186/1471-2210-3-1 Text en Copyright © 2003 Gharagozlou et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Gharagozlou, Parham
Demirci, Hasan
David Clark, J
Lameh, Jelveh
Activity of opioid ligands in cells expressing cloned mu opioid receptors
title Activity of opioid ligands in cells expressing cloned mu opioid receptors
title_full Activity of opioid ligands in cells expressing cloned mu opioid receptors
title_fullStr Activity of opioid ligands in cells expressing cloned mu opioid receptors
title_full_unstemmed Activity of opioid ligands in cells expressing cloned mu opioid receptors
title_short Activity of opioid ligands in cells expressing cloned mu opioid receptors
title_sort activity of opioid ligands in cells expressing cloned mu opioid receptors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140036/
https://www.ncbi.nlm.nih.gov/pubmed/12513698
http://dx.doi.org/10.1186/1471-2210-3-1
work_keys_str_mv AT gharagozlouparham activityofopioidligandsincellsexpressingclonedmuopioidreceptors
AT demircihasan activityofopioidligandsincellsexpressingclonedmuopioidreceptors
AT davidclarkj activityofopioidligandsincellsexpressingclonedmuopioidreceptors
AT lamehjelveh activityofopioidligandsincellsexpressingclonedmuopioidreceptors